The University of Cincinnati (UC) Medical Center's Southwest Oncology Group (SWOG) activities center on hospitals of The Health Alliance of Greater Cincinnati. These four hospitals (University Hospital, The Christ Hospital, St. Luke Hospitals, and The Jewish Hospitals) plus the Veterans Affairs Medical Center Hospital are the core of clinical cancer research activities that also extend to several affiliated institutions. Patients served by The Health Alliance are drawn from a large population base which includes a significant minority population. The UC SWOG program has dramatically increased its productivity since its inception six years ago. Specifically, their accruals have increased fourfold from 21 in 1992 to 85 in 1996. Over the same time period, minority accruals have risen from 1 to 25. This growth is partly a reflection of institutional support from UC (the Vice-Provost of Health Affairs, the Dean of the College of Medicine, Department of Medicine Chair, Hematology-Oncology Division Director) and from The Health Alliance. It is also a reflection of enthusiastic physician investigators committed to providing patients with state-of-the-art clinical care and opportunities for participation in NCI sponsored clinical research. The UC SWOG physician investigators are poised to continue significant creative contributions in protocol design and development and to contribute administratively in numerous committees. The major role of UC in the Pathology Discipline committee (including housing of the SWOG tumor bank at UC) further establishes University of Cincinnati's SWOG program as one with the resources and commitment to be an effective and productive SWOG member institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA076429-01
Application #
2453105
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1998-04-01
Project End
2002-12-31
Budget Start
1998-04-01
Budget End
1998-12-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Press, Oliver W; Unger, Joseph M; Rimsza, Lisa M et al. (2013) A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res 19:6624-32

Showing the most recent 10 out of 58 publications